News about Global Pharma

Egypt to Establish USD 120 Million Pharmaceutical Hub in Suez Canal Economic Zone

The project will be located within SCZONE's Sokhna Integrated Industrial Zone and will span an area of 96,828 square meters.

Global Pharma | 04/01/2025 | By Abha |  1111

Karyopharm Welcomes Lori Macomber as its New Chief Financial Officer

Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies.

Global Pharma | 03/01/2025 | By Aishwarya |  383

Shanghai MicuRx's MRX-5 Receives FDA Orphan Drug Designation for NTM Infections

MRX-5 is a novel benzoxazole antibiotic developed for treating mycobacteria infections, particularly infections caused by non-tuberculous mycobacteria (NTM).

Global Pharma | 03/01/2025 | By Abha |  501

Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC

China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).

Global Pharma | 03/01/2025 | By Abha |  308

Veeda Group Announces Rebranding of its Identity as Veeda Lifesciences

Veeda Lifesciences represents the brand that integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India, showcasing research services across various stages of the drug development value chain from discovery and preclinical to late-phase development.

Global Pharma | 03/01/2025 | By Aishwarya |  584

CORXEL Signs Agreement with Sanofi for Aficamten in Greater China Markets

Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics.

Global Pharma | 02/01/2025 | By Aishwarya |  478

Lupin Acquires Huminsulin from Lilly to Strengthen Diabetes Portfolio

Lupin has acquired the Huminsulin range from Eli Lilly in India, strengthening its diabetes portfolio with treatments for type 1 and type 2 diabetes mellitus.

Global Pharma | 02/01/2025 | By Manvi |  257

WuXi Biologics, Sino Biopharm Ink Discovery Service Agreement for First-in-Class mAb

WuXi Biologics has signed a service agreement with Sino Biopharm to discover a first-in-class monoclonal antibody (mAb) using its advanced discovery platforms.

Global Pharma | 02/01/2025 | By Manvi |  258

Innovent Signs Exclusive Global License Deal with Roche for Novel DLL3 Antibody Drug Conjugate

IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors.

Global Pharma | 02/01/2025 | By Aishwarya |  430

NRx Pharmaceuticals Advances NRX-100 NDA Submission to FDA for Suicidal Depression Treatment

NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for the treatment of suicidal bipolar depression.

Global Pharma | 01/01/2025 | By Abha |  600